Literature DB >> 22999546

Stage, grade and behavior of bladder urothelial carcinoma defined by the microRNA expression profile.

Nelson Dip1, Sabrina T Reis, Luciana S Timoszczuk, Nayara I Viana, Camila B Piantino, Denis R Morais, Caio M Moura, Daniel K Abe, Iran A Silva, Miguel Srougi, Marcos F Dall'Oglio, Katia R M Leite.   

Abstract

PURPOSE: We identified miRNA expression profiles in urothelial carcinoma that are associated with grade, stage, and recurrence-free and disease specific survival.
MATERIALS AND METHODS: The expression of 14 miRNAs was evaluated by quantitative reverse transcriptase-polymerase chain reaction in surgical specimens from 30 patients with low grade, noninvasive (pTa) and 30 with high grade, invasive (pT2-3) urothelial carcinoma. Controls were normal bladder tissue from 5 patients who underwent surgical treatment for benign prostatic hyperplasia. Endogenous controls were RNU-43 and RNU-48. miRNA profiles were compared and Kaplan-Meier curves were constructed to analyze disease-free and disease specific survival.
RESULTS: miR-100 was under expressed in 100% of low grade pTa specimens (p <0.001) and miR-10a was over expressed in 73.3% (p <0.001). miR-21 and miR-205 were over expressed in high grade pT2-3 disease (p = 0.02 and <0.001, respectively). The other miRNAs were present at levels similar to those of normal bladder tissue or under expressed in each tumor group. miR-21 over expression (greater than 1.08) was related to shorter disease-free survival in patients with low grade pTa urothelial carcinoma. Higher miR-10a levels (greater than 2.30) were associated with shorter disease-free and disease specific survival in patients with high grade pT2-3 urothelial carcinoma.
CONCLUSIONS: Four miRNAs were differentially expressed in the 2 urothelial carcinoma groups. miR-100 and miR-10a showed under expression and over expression, respectively, in low grade pTa tumors. miR-21 and miR-205 were over expressed in pT2-3 disease. In addition, miR-10a and miR-21 over expression was associated with shorter disease-free and disease specific survival. miRNAs could be incorporated into the urothelial carcinoma molecular pathway. These miRNAs could also serve as new diagnostic or prognostic markers and new target drugs.
Copyright © 2012 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22999546     DOI: 10.1016/j.juro.2012.07.004

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  16 in total

1.  XRN2 promotes EMT and metastasis through regulating maturation of miR-10a.

Authors:  H Zhang; Y Lu; E Chen; X Li; B Lv; H G Vikis; P Liu
Journal:  Oncogene       Date:  2017-03-20       Impact factor: 9.867

Review 2.  Potential role of miR-100 in cancer diagnosis, prognosis, and therapy.

Authors:  Chu Qin; Ru-Yi Huang; Zhao-Xia Wang
Journal:  Tumour Biol       Date:  2015-03-05

3.  Circulating miR-205: a promising biomarker for the detection and prognosis evaluation of bladder cancer.

Authors:  Zhenqiang Fang; Wei Dai; Xiangwei Wang; Wei Chen; Chongxin Shen; Gang Ye; Longkun Li
Journal:  Tumour Biol       Date:  2015-12-29

Review 4.  MicroRNAs: Key Players in Bladder Cancer.

Authors:  Qi Li; Helei Wang; Hourong Peng; Qiuping Huang; Ting Huyan; Qingsheng Huang; Hui Yang; Junling Shi
Journal:  Mol Diagn Ther       Date:  2019-10       Impact factor: 4.074

5.  Can increased expression of miR-Let-7c reduce the transition potential of high-grade urothelial carcinoma?

Authors:  Paulo Ricardo da Silva Gomes; Patricia Candido; Vitória Ghazarian; Juliana A Camargo; Vanessa R Guimarães; Guilherme L Gonçalves; Poliana Romão; Iran A Silva; Miguel Srougi; William C Nahas; Kátia R Leite; Sabrina T Reis; Ruan Pimenta; Nayara Izabel Viana
Journal:  Mol Biol Rep       Date:  2021-10-27       Impact factor: 2.316

Review 6.  Prognostic and predictive miRNA biomarkers in bladder, kidney and prostate cancer: Where do we stand in biomarker development?

Authors:  Maria Schubert; Kerstin Junker; Joana Heinzelmann
Journal:  J Cancer Res Clin Oncol       Date:  2015-12-12       Impact factor: 4.553

7.  Increased miR-141 expression is associated with diagnosis and favorable prognosis of patients with bladder cancer.

Authors:  Xiao-Lin Wang; Hu-Yang Xie; Chuan-Dong Zhu; Xiao-Fang Zhu; Guang-Xin Cao; Xiao-Hong Chen; Han-Feng Xu
Journal:  Tumour Biol       Date:  2014-10-11

8.  Gene and isoform expression signatures associated with tumor stage in kidney renal clear cell carcinoma.

Authors:  Qi Liu; Shilin Zhao; Pei-Fang Su; Shyr Yu
Journal:  BMC Syst Biol       Date:  2013-12-09

9.  Analysis of tissue and serum microRNA expression in patients with upper urinary tract urothelial cancer.

Authors:  Stephanie Kriebel; Doris Schmidt; Stefan Holdenrieder; Diane Goltz; Glen Kristiansen; Rudolf Moritz; Christian Fisang; Stefan C Müller; Jörg Ellinger
Journal:  PLoS One       Date:  2015-01-28       Impact factor: 3.240

10.  Evaluation of miR-141, miR-200c, miR-30b Expression and Clinicopathological Features of Bladder Cancer.

Authors:  Ali Mahdavinezhad; Seyed Habibollah Mousavi-Bahar; Jalal Poorolajal; Reza Yadegarazari; Mohammad Jafari; Nooshin Shabab; Massoud Saidijam
Journal:  Int J Mol Cell Med       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.